Advertisements


Alexion to present results from ALXN1210 Phase 3 study at EHA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 14th, 2018

Karyopharm to present Phase 2 SEAL study results at ASCO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 16th, 2018

Calithera to present results from Phase 1 CB-839 combination study at ASCO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2018

Alexion to present "positive" Phase 3 data for ALXN1210 at ASH meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 3rd, 2018

Alexion reports "positive" results from Phase 3 study of ULTOMIRIS

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 28th, 2019

NewLink Genetics to present Phase 2 NLG207 study results at AACR

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 27th, 2019

Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical studies ex.....»»

Category: earningsSource: benzingaMay 24th, 2019

Why Ocular Therapeutix Fell Short in Its Glaucoma Study

Ocular Therapeutix shares took a beating on Tuesday after the firm announced late-stage results for patients with primary open-angle glaucoma or ocular hypertension. These results come from the Phase........»»

Category: blogSource: 247wallstMay 21st, 2019

Solid Breast Cancer Results From MacroGenics Ahead of ASCO

MacroGenics announced additional details of the results from the Phase 3 Sophia study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with........»»

Category: blogSource: 247wallstMay 16th, 2019

AstraZeneca to present results from Phase III POLO trial at ASCO meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 16th, 2019

Magenta Therapeutics expects to present data from Phase 1 MGTA-145 study in 2019

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 9th, 2019

Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results

- Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight and hunger responses in patients with high-i.....»»

Category: earningsSource: benzingaMay 3rd, 2019

Vistagen Shares Fall Under $1 After Depression Drug Flunks Midstage Trial

Vistagen Therapeutics Inc (NASDAQ: VTGN) shares were nearly cut in half Thursday following adverse results from a Phase 2 study evaluating its treatment-resistant depression (TRD) drug candidate. read more.....»»

Category: blogSource: benzingaMay 2nd, 2019

Seres expects to obtain SER-401 Phase 1b preliminary study results in 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 2nd, 2019

Xeris Pharmaceuticals announces results from Phase 1 diazepam study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 1st, 2019

Aptinyx reports results from NYX-458 Phase 1 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 30th, 2019

Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update

ACHIEVE trial completed – inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profile Phase 2 co-administration study of inarigi.....»»

Category: earningsSource: benzingaApr 29th, 2019

Merck"s Keytruda no better than chemo as a first-line treatment for gastric cancer, according to Phase 3 study results

Merck & Co. Inc. said Friday that a Phase 3 trial evaluating Keytruda as a first-line treatment for gastric cancer failed to show improvement in patients' overall or progression-free survival when compared with chemotherapy. Shares of th.....»»

Category: topSource: marketwatchApr 26th, 2019

Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on.....»»

Category: personnelSource: nytApr 16th, 2019

Biofrontera reports secondary endpoint results from Phase 3 PDT study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2019

Wave Life Sciences presents final results from Phase 1 suvodirsen study at MDA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2019